TNF and juvenile idiopathic arthritis: B cell depletion therapy with rituximab is a treatment option considered in JIA patients refractory to first-line biologic treatments such as TNF inhibitors, which has been shown to be an effective and well-tolerated treatment in children with JIA, supporting B cell involvement in JIA pathogenesis.